Reliance Industries-subsidiary Reliance Digital Health, with Synchron Inc, signed the agreement to acquire a 2.25% stake in the Series C financing round.

• HDFC Bank Lags Peers as Governance Review Clouds Sector Rally
• Fino Payments Bank Climbs 10% After Strong May Business Update
• Panacea Biotec Surges 15% as EU-Funded Dengue Vaccine Project Goes Live
• JNK India Jumps 12.5% After Bagging Large UAE Order for Abu Dhabi Project
• RVNL Shares Gain 3% on Securing Rs 221 Crore Contract 

The company has been developing the BCI platform, which avoided craniotomy in 2012 by using minimally invasive procedures. The Synchron Switch BCI received FDA Breakthrough Device Designation in Australia and the US in 2020.

On December 15, to raise funds after an oversubscribed $75 million Series C financing round led by ARCH Venture Partners. Bezos Expeditions, Gates Frontier, Reliance Digital Health Limited, Moore Strategic Ventures, Greenoaks, Alumni Ventures, and Project X join ARCH as new additional investors.

NeuroTechnology Investors, Khosla Ventures, Forepont Capital Partners, METIS, ID8 Investments University of Melbourne and Shanda Group are already in existence. The Series C funding brings the total funds raised since inception to $145 million. On BSE, RIL’s shares hit a high of 0.92% to Rs 2602.40.